Hologic (HOLX) announced that the FDA has granted 510(k) clearance for the Panther Fusion gastrointestinal bacterial and expanded bacterial assays. The company also announced that the assays obtained CE marking in the European Union in accordance with in vitro diagnostic regulation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Minicarm.com named U.S. distributor of Fluoroscan Insight FD Mini C-Arm
- VolitionRx signs co-marketing and services agreement with Hologic
- Hologic’s Growth Potential: Hold Rating Amidst Uncertainties and Transient Headwinds
- Hologic Extends CEO Stephen MacMillan’s Employment Agreement
- Hologic Stock (HOLX) Climbs as Blackstone and TPG Renew Take-Private Bid